Revolutionizing Healthcare: A Scientist's Plea for Patient-Centric Treatments
A groundbreaking call to action is being made by Precious Akinnusi, a doctoral researcher at the University of Cincinnati. He passionately advocates for a paradigm shift in healthcare, urging the medical community to embrace patient-centered therapies. Akinnusi believes that the true effectiveness of medications lies in tailoring treatment designs to patients' everyday lives.
In an insightful interview, Akinnusi reveals that his research delves into biomaterials-based drug delivery systems, placing patients at the heart of the care process. He emphasizes, "The key to successful treatment design lies in understanding patients' daily routines. Instead of burdening patients with complex therapies, we should strive to seamlessly integrate drug delivery systems into their daily lives."
His research takes a unique approach by focusing on the skin as a strategic treatment site. Akinnusi aims to develop innovative delivery systems that localize treatment within skin tissues, especially for conditions like skin cancer. By concentrating therapy at the disease site, he believes it's possible to minimize side effects and enhance overall effectiveness. Furthermore, Akinnusi explores the skin as a gateway to systemic circulation, offering an intriguing alternative to traditional injections or oral medications.
But here's where it gets intriguing: Akinnusi's journey from drug discovery to drug delivery is not just a professional choice but a natural evolution. He explains, "Identifying a drug is just the beginning. The real challenge is ensuring the delivery method aligns with the patient's needs. If we neglect this aspect, we might never unlock the full potential of our scientific discoveries."
Akinnusi's background in biochemistry, honed at Adekunle Ajasin University, laid the foundation for his research. He initially focused on identifying bioactive plant molecules and their interactions with disease pathways, employing both biochemical analysis and computational techniques. One of his studies on COVID-19 stands out, where he investigated anthocyanins and their interactions with various SARS-CoV-2 proteins involved in viral entry and replication.
And this is the part most researchers miss: Akinnusi's study took a unique approach by examining the dynamic nature of the virus. Instead of targeting a single pathway, he explored how individual compounds interacted with different viral mechanisms. This led to the discovery of a compound, cyanidin 3-O-glucosyl-rutinoside, which consistently bound to all five proteins studied. Akinnusi highlights the importance of stability and safety assessments, stating, "A compound might bind well initially but fail later. Early evaluation is crucial to avoid missing critical insights."
This research highlights a controversial yet essential aspect of drug development: the need to consider patient-centric delivery methods alongside drug discovery. It challenges the traditional approach and invites discussion on how we can revolutionize healthcare by putting patients at the center of treatment design.
